[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605351":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":172,"collaborators":10,"id":174,"slug":175,"hasResults":176,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":176,"sex":182,"minAge":183,"maxAge":10,"enrollmentInfo":184,"targetDuration":10,"studyType":187,"phases":10,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":202},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"LS-SCLC",null,"Patients with LS-SCLC who received platinum-based cCRT\u002FsCRT followed by durvalumab consolidation as first line treatment at the discretion of physicians.",[13],{"name":14,"affiliation":15,"role":16},"JinMing Yu, Doctor","Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital)","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[24,36,43,50,57,64,71,79,83,90,97,104,111,118,125,132,139,144,151,158,165],{"facility":25,"status":26,"city":27,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":10},"Research Site","RECRUITING","Beijing","China","CN",{"type":31,"coordinates":32},"Point",[33,34],116.39723,39.9075,{"lat":34,"lon":33},{"facility":25,"status":26,"city":37,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":38,"geoPoint":42,"contacts":10},"Cangzhou",{"type":31,"coordinates":39},[40,41],116.85334,38.31124,{"lat":41,"lon":40},{"facility":25,"status":26,"city":44,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":45,"geoPoint":49,"contacts":10},"Dongguan",{"type":31,"coordinates":46},[47,48],113.74866,23.01797,{"lat":48,"lon":47},{"facility":25,"status":26,"city":51,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":52,"geoPoint":56,"contacts":10},"Fuzhou",{"type":31,"coordinates":53},[54,55],119.30611,26.06139,{"lat":55,"lon":54},{"facility":25,"status":26,"city":58,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":59,"geoPoint":63,"contacts":10},"Guangzhou",{"type":31,"coordinates":60},[61,62],113.25,23.11667,{"lat":62,"lon":61},{"facility":25,"status":26,"city":65,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":66,"geoPoint":70,"contacts":10},"Huzhou",{"type":31,"coordinates":67},[68,69],120.0933,30.8703,{"lat":69,"lon":68},{"facility":25,"status":26,"city":72,"state":10,"zip":73,"country":28,"countryCode":29,"cosmosGeoPoint":74,"geoPoint":78,"contacts":10},"Jinan","250117",{"type":31,"coordinates":75},[76,77],116.99722,36.66833,{"lat":77,"lon":76},{"facility":25,"status":26,"city":72,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":80,"geoPoint":82,"contacts":10},{"type":31,"coordinates":81},[76,77],{"lat":77,"lon":76},{"facility":25,"status":26,"city":84,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":85,"geoPoint":89,"contacts":10},"Nanjing",{"type":31,"coordinates":86},[87,88],118.77778,32.06167,{"lat":88,"lon":87},{"facility":25,"status":26,"city":91,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":92,"geoPoint":96,"contacts":10},"Nanning",{"type":31,"coordinates":93},[94,95],108.31667,22.81667,{"lat":95,"lon":94},{"facility":25,"status":26,"city":98,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":99,"geoPoint":103,"contacts":10},"Ningbo",{"type":31,"coordinates":100},[101,102],121.54945,29.87819,{"lat":102,"lon":101},{"facility":25,"status":26,"city":105,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":106,"geoPoint":110,"contacts":10},"Shanghai",{"type":31,"coordinates":107},[108,109],121.45806,31.22222,{"lat":109,"lon":108},{"facility":25,"status":26,"city":112,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":113,"geoPoint":117,"contacts":10},"Shenyang",{"type":31,"coordinates":114},[115,116],123.43278,41.79222,{"lat":116,"lon":115},{"facility":25,"status":26,"city":119,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":120,"geoPoint":124,"contacts":10},"Shijiazhuang",{"type":31,"coordinates":121},[122,123],114.47861,38.04139,{"lat":123,"lon":122},{"facility":25,"status":26,"city":126,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":127,"geoPoint":131,"contacts":10},"Taiyuan",{"type":31,"coordinates":128},[129,130],112.56028,37.86944,{"lat":130,"lon":129},{"facility":25,"status":26,"city":133,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":134,"geoPoint":138,"contacts":10},"Tianjing",{"type":31,"coordinates":135},[136,137],120.77196,31.46583,{"lat":137,"lon":136},{"facility":25,"status":140,"city":133,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":141,"geoPoint":143,"contacts":10},"TERMINATED",{"type":31,"coordinates":142},[136,137],{"lat":137,"lon":136},{"facility":25,"status":26,"city":145,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":146,"geoPoint":150,"contacts":10},"Wuhan",{"type":31,"coordinates":147},[148,149],114.26667,30.58333,{"lat":149,"lon":148},{"facility":25,"status":26,"city":152,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":153,"geoPoint":157,"contacts":10},"Wuxi",{"type":31,"coordinates":154},[155,156],120.28857,31.56887,{"lat":156,"lon":155},{"facility":25,"status":26,"city":159,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":160,"geoPoint":164,"contacts":10},"Yangzhou",{"type":31,"coordinates":161},[162,163],119.43583,32.39722,{"lat":163,"lon":162},{"facility":25,"status":26,"city":166,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":167,"geoPoint":171,"contacts":10},"Zhengzhou",{"type":31,"coordinates":168},[169,170],113.64861,34.75778,{"lat":170,"lon":169},{"type":173,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100605351","durvalumab-consolidation-after-chemoradiation-therapy-for-limited-stage-sclc-in-china-100605351",false,"NCT07161388","Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China","Durvalumab Consolidation After Chemoradiation Therapy (CRT) for Patients With Limited Stage Small-Cell Lung Cancer in China: A Multicentre, Observational Study (DREAM)","DREAM","Inclusion Criteria:\n\n* Able to provide informed consent\n* Age ≥18 years\n* Histologically or cytologically documented LS-SCLC (Stage I-III SCLC \\[T any, N any, M0\\] according to the American Joint Committee on Cancer Staging Manual \\[AJCC Cancer Staging Manual, 8th Edition\\], that can be safely treated with definitive radiation doses. Excludes T3-4 due to multiple lung nodules that are too extensive or have tumor\u002Fnodal volume that is too large to be encompassed in a tolerable radiation plan)\n* ECOG PS 0-2 (prior to the first dose of durvalumab after CRT)\n* No disease progression following cCRT\u002FsCRT (cCRT refers to chemotherapy and radiotherapy are administered with overlap; sCRT refers to chemotherapy and radiotherapy are delivered in a sequential manner with no overlap)\n* Patients who received platinum-based cCRT\u002FsCRT followed by durvalumab consolidation as first-line treatment at the discretion of physicians are eligible (the time interval from the end of cCRT\u002FsCRT to the first dose of durvalumab consolidation should be within 3 months)\n\n  * Patients who started durvalumab consolidation ≤3 months before enrolment in the study will be allowed (irrespective of whether they continue to receive durvalumab at time of enrolment or already discontinued treatment)\n\nExclusion Criteria:\n\n* Patients treated with CRT only without subsequent durvalumab consolidation\n* Patients received durvalumab or any other anti-PD-1\u002Fanti-PD-L1 antibodies along with CRT\n* Patients who previously were involved, or currently are, or plan to be involved in any other interventional anti-cancer clinical studies for LS-SCLC\n* Prior exposure to immune-mediated therapy including, but not limited to, other anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic anticancer vaccines\n* Judgment by the investigator that the patient should not participate in the study because the patient is unlikely to comply with study procedures","ALL","18 Years",{"count":185,"type":186},200,"ESTIMATED","OBSERVATIONAL","This prospective, multicentre, observational study aims to assess the effectiveness and safety of durvalumab as consolidation treatment for patients with LS-SCLC who have not progressed following CRT in real-world setting.",[190],"Limited Stage Small-Cell Lung Cancer",[192],"SCLC","2026-06-23",{"date":195,"type":196},"2026-06-24","ACTUAL",{"date":198,"type":196},"2025-11-17",{"date":200,"type":186},"2028-09-30",{"name":5,"class":6},21]